Yvonne Linney Net Worth

The estimated Net Worth of Yvonne Linney is at least $9.6 Thousand dollars as of 15 August 2022. Yvonne Linney owns over 20,000 units of Bionano Genomics Inc stock worth over $9,600 and over the last 5 years he sold BNGO stock worth over $0. In addition, he makes $0 as Director at Bionano Genomics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Yvonne Linney BNGO stock SEC Form 4 insiders trading

Yvonne has made over 1 trades of the Bionano Genomics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BNGO stock worth $7,600 on 15 August 2022.

The largest trade he's ever made was exercising 20,000 units of Bionano Genomics Inc stock on 15 August 2022 worth over $7,600. On average, Yvonne trades about 2,500 units every 0 days since 2020. As of 15 August 2022 he still owns at least 20,000 units of Bionano Genomics Inc stock.

You can see the complete history of Yvonne Linney stock trades at the bottom of the page.

Yvonne Linney biography

Dr. Yvonne Linney Ph.D. serves as Director of the Company. Yvonne Linney founded Linney BioConsulting, an advisory and strategy development firm in the life sciences industry, in January 2019. Dr. Linney has served as a strategic advisor to General Automation Laboratory Technologies (GALT) since November 2019, SRI International since June 2019, the California Life Sciences Institute since March 2019, and to Tag.bio, Inc. since January 2019. From January 2017 to November 2018, Dr. Linney served as the Chief Executive Officer of Transcriptic Inc. (now Strateos, Inc.), a private company that developed a robotic cloud laboratory platform, where she had previously served as Chief Operating Officer since October 2015. Dr. Linney also served on Transcriptic's Board of Directors from December 2016 to November 2018. In addition, from November 2006 to January 2015, Dr. Linney served as Executive Vice President and General Manager, Life Sciences at Agilent Technologies, Inc., a public life sciences and diagnostics company. Prior to joining Agilent, Dr. Linney served as Director of Molecular Diagnostics and Global Strategic Marketing at Bayer Diagnostics (now part of Siemens Healthcare) from 2005 to 2006 and Senior Director, Marketing and Product Management at Caliper Life Sciences from 2003 to 2005. Dr. Linney also served as Director of Genomics at Amersham International (now GE Healthcare) from 1993 to 2003. Dr. Linney holds a BS in microbiology and virology from Warwick University, UK, and a Ph.D. in genetics from Leicester University, UK.

What's Yvonne Linney's mailing address?

Yvonne's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.

Insiders trading at Bionano Genomics Inc

Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart, and Christopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.

What does Bionano Genomics Inc do?

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o

Complete history of Yvonne Linney stock trades at Bionano Genomics Inc

Bionano Genomics Inc executives and stock owners

Bionano Genomics Inc executives and other stock owners filed with the SEC include:

• R. Erik Holmlin,
  President, Chief Executive Officer, Director
• Mark Oldakowski,
  Chief Operating Officer
• Dr. Robert Erik Holmlin,
  Pres, CEO, Sec. & Director
• David Barker,
  Independent Chairman of the Board
• Christopher P. Stewart,
  Chief Financial Officer
• Kristiina Vuori,
  Independent Director
• Christopher Twomey,
  Independent Director
• Albert Luderer,
  Independent Director
• Hannah Mamuszka,
  Director
• Yvonne Linney,
  Director
• Alka Chaubey,
  Chief Medical Officer
• Christopher Stewart,
  Chief Financial Officer
• Dr. Charles Lee Ph.D.,
  Scientific Advisor
• Prof. Pui-Yan Kwok,
  Scientific Advisor
• Dr. Paul R. Selvin Ph.D.,
  Scientific Advisor
• Mark Adamchak,
  Controller
• Richard Shippy,
  Chief Bus. Officer
• Robert J. Priar,
  Chief Commercial Officer
• Dr. Alka Chaubey FACMG, Ph.D.,
  Chief Medical Officer
• Aleksandar Rajkovic,
  Director
• Robert J Priar,
  Chief Commercial Officer
• Michael James Ward,
  Former Chief Financial Officer
• Heather Adams,
  Chief Administrative Officer
• Warren Robinson,
  Chief Commercial Officer
• Darren Cai,
  Director
• Quan Zhou,
  Director
• Junfeng Wang,
  Director
• Soheil Shams,
  Chief Informatics Officer
• Richard Shippy,
  Chief Business Officer
• Vincent Jung Fai Wong,
  Director
• Jonathan V. Dixon,
  GENERAL COUNSEL
• Gulsen Kama,
  Chief Financial Officer